Warning: SGLT2 Inhibitors

The FDA is warning that SGLT2 (sodium-glucose cotransporter-2) Inhibitors, diabetes drugs such as canagliflozin, dapagliflozin, or empagliflozin, can produce ketoacidosis which may result in life-threatening blood infections (urosepsis) and kidney infections (pyelonephritis) that start as urinary tract infections.  The FDA advises that patients stop taking their SGLT2 inhibitor and seek medical attention immediately if they have any symptoms of ketoacidosis, which include nausea, vomiting, abdominal pain, tiredness, and trouble breathing.  For full details see http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm475553.htm .

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s